Kobayashi Pharmaceutical is considering going private. Following a tender offer (TOB) proposal from investment funds, the founding family is also believed to be considering investing.
Kobayashi Pharmaceutical was found on the 24th to be considering going private. 日本産業推進機構 and European fund CVC Capital Partners, which are planning a TOB to advance management reforms under the umbrella of investment funds and achieve the take-private transaction, are at the core of the proposal. The founding family is also believed to be considering investing.
The proposed TOB is said to involve acquiring shares in the open market to take the company private. The apparent aim is to establish a stable management structure after the take-private transaction, prompting speculation that corporate governance reforms and a management turnaround will be pursued under the funds' ownership.
Kobayashi Pharmaceutical disclosed the health damage issue in March 2024, and this is said to have created pressure for corporate governance reform. If the take-private transaction is completed, some observers believe it could facilitate a systematic turnaround and the advancement of reforms.